Solid Biosciences’ DMD Gene Therapy Undermined By Safety Wobbles

 
• By Alexandra Shimmings

Another setback for the novel therapy leaves rivals Sarepta and Pfizer in a stronger position in a potentially highly rewarding market.

Seismograph
Not so Solid Ground for the DMD therapy • Source: Shutterstock

More from Clinical Trials

More from R&D